Skip to main content

MS news

Our news web pages include ground-breaking multiple sclerosis news and research from around the world. 

These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.

Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content. If you have any issues relating to the topics here, please call the MS-UK Helpline on 0800 7830 518.


 

Roche has announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of ocrelizumab for the treatment of relapsing multiple sclerosis...

The multiple sclerosis drug Gilenya may help patients by directly enhancing nerve regeneration and increasing myelination in a way that is partly independent of its anti-inflammatory properties....

Rituximab may be an possible treatment option for patients with relapsing-remitting multiple sclerosis (MS), researchers say, after phase II study findings found its efficacy in controlling...

Scientists of the Technical University of Munich (TUM) and the Max Planck Institute of Psychiatry have identified four new risk genes that are altered in German patients with multiple sclerosis (...

Taste deficits appear to be more prevalent among multiple sclerosis (MS) patients than previously reported and correlate with brain lesions left, a new study from the University of Pennsylvania's...

Leaky blood vessels in the brain called cerebral microbleeds are associated with increased physical and cognitive disability in patients with multiple sclerosis (MS), according to a new study by...

Oligodendrocytes, a type of brain cell that plays a crucial role in conditions such as multiple sclerosis, are more diverse than have previously been thought, according to a new study by...

A radical and risky stem cell therapy has been shown to halt and even reverse some of the symptoms of those worst affected by multiple sclerosis, a condition that in many people has proved...

Biogen has been bit by the failure of its multiple sclerosis candidate opicinumab to show efficacy in a phase II trial.

The news is disappointing as the antibody had been proposed as a...

Research from Indiana University School of Medicine has found that D3T – a compound that triggers copying of antioxidant genes and production of the antioxidant glutathione – delays disease...

Pages

Live Chat Software by Click4Assistance UK